Results 1 to 10 of about 878,335 (267)

Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation [PDF]

open access: hybridBlood, 2001
Receptors for human immunoglobulin (Ig)G and IgA initiate potent cytolysis of antibody (Ab)-coated targets by polymorphonuclear leukocytes (PMNs). Mac-1 (complement receptor type 3, CD11b/CD18) has previously been implicated in receptor cooperation with ...
Annemiek B. van Spriel   +6 more
openalex   +2 more sources

Wiskott–Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses [PDF]

open access: greenProceedings of the National Academy of Sciences of the United States of America, 2002
The Wiskott–Aldrich syndrome (WAS) is a primary immunodeficiency disorder caused by a mutation in WAS protein (WASp) that results in defective actin polymerization.
Jordan S. Orange   +9 more
openalex   +2 more sources

Immunologic Cytotoxicity in Alopecia Areata: Apoptosis of Dermal Papilla Cells in Alopecia Areata

open access: bronzeJournal of Investigative Dermatology, 1995
David A. Nortis   +3 more
openalex   +2 more sources

Single‐cell profiling identifies distinct hormonal, immunologic, and inflammatory signatures of endometriosis‐constituting cells

open access: yesJournal of Pathology, 2023
Endometriosis consists of ectopic endometrial epithelial cells (EEECs) and ectopic endometrial stromal cells (EESCs) mixed with heterogeneous stromal cells.
Sun Shin   +6 more
semanticscholar   +1 more source

Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets.

open access: yesJournal of Investigative Dermatology, 1990
Immunologic cytotoxicity is an important endpoint of the immune response to tumors, viral infected cells, grafted tissues, and exogenous microorganisms, and is also an important mechanism of disease, especially in autoimmunity.
David A. Norris
semanticscholar   +1 more source

Stochastic model of T Cell repolarization during target elimination (II) [PDF]

open access: yes, 2021
Cytotoxic T lymphocytes (T cells) and natural killer cells form a tight contact, the immunological synapse (IS), with target cells, where they release their lytic granules containing perforin/granzyme and cytokine containing vesicles. During this process the cell repolarizes and moves the microtubule organizing center (MTOC) towards the IS.
arxiv   +1 more source

Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling.

open access: yesCancer Research, 2006
The ability of cancers to evade immune surveillance and resist immunotherapy raises a fundamental question of how tumor cells survive in the presence of a competent immune system.
R. Ravi   +12 more
semanticscholar   +1 more source

Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity.

open access: yesCancer Research, 2018
Elucidation of the underlying molecular mechanisms of immune evasion in cancer is critical for the development of immunotherapies aimed to restore and stimulate effective antitumor immunity.
Antoun Al Absi   +14 more
semanticscholar   +1 more source

Stochastic model of T Cell repolarization during target elimination (I) [PDF]

open access: yes, 2020
Cytotoxic T lymphocytes (T) and natural killer (NK) cells are the main cytotoxic killer cells of the human body to eliminate pathogen-infected or tumorigenic cells (i.e. target cells). Once a NK or T cell has identified a target cell, they form a tight contact zone, the immunological synapse (IS).
arxiv   +1 more source

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials [PDF]

open access: yesStatistical Science 2010, Vol. 25, No. 2, 227-244, 2010
An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "phase I/II" trials, these experiments typically have the nominal scientific goal of determining an acceptable dose, most often based on adverse event probabilities.
arxiv   +1 more source

Home - About - Disclaimer - Privacy